Tissue fibrosis is a major cause of mortality that results from the deposition of matrix proteins
by an activated mesenchyme. Macrophages accumulate in fibrosis, but the role of specific …

Idiopathic pulmonary fibrosis (IPF) is a fatal disease with incompletely understood aetiology
and limited treatment options. Traditionally, IPF was believed to be mainly caused by …

Interstitial lung fibrosis can develop as a consequence of occupational or medical exposure,
as a result of genetic defects, and after trauma or acute lung injury leading to …

A key feature of pulmonary fibrosis is the presence of fibroblasts at sites of active fibrosis. In
fact, the presence of a distinct lesion, termed a" fibroblastic focus," composed of fibroblasts …

There are currently few treatment options for pulmonary fibrosis. Innovations may come from
a better understanding of the cellular origin of the characteristic fibrotic lesions. We have …

The preclinical model of bleomycin-induced lung fibrosis, used to investigate mechanisms
related to idiopathic pulmonary fibrosis (IPF), has incorrectly predicted efficacy for several …

Idiopathic pulmonary fibrosis (IPF) is the most frequent fibrotic diffuse parenchymal lung
disease. Its prognosis is devastating:> 50% of the patients die within 3 years after diagnosis …

The pathogenesis of pulmonary fibrosis remains incompletely understood. Studies of
associated inflammation have led to the discovery of a number of cytokines and chemokines …

Background Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic interstitial lung
disease that is unresponsive to current therapy and often leads to death. However, the rate …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, incurable lung disease of
unknown etiology with only limited treatment options. Current paradigms of disease …